{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:17:20Z","timestamp":1790605040869,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016350","name":"Sichuan Provincial Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["2021ZD01"],"award-info":[{"award-number":["2021ZD01"]}],"id":[{"id":"10.13039\/501100016350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","award":["2021YFS0271"],"award-info":[{"award-number":["2021YFS0271"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.rmed.2023.107329","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T12:46:11Z","timestamp":1686573971000},"page":"107329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"216","author":[{"given":"Mei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiawei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.rmed.2023.107329_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168952","article-title":"Fibrotic idiopathic interstitial lung disease: the molecular and cellular key players","volume":"22","author":"Samarelli","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.rmed.2023.107329_bib2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2023.107329_bib3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00408-020-00383-w","article-title":"Connective tissue disease-related interstitial lung disease: prevalence, patterns, predictors, prognosis, and treatment","volume":"198","author":"Jeganathan","year":"2020","journal-title":"Lung"},{"issue":"5","key":"10.1016\/j.rmed.2023.107329_bib4","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.semarthrit.2020.07.011","article-title":"Risk of interstitial lung disease in patients with newly diagnosed systemic autoimmune rheumatic disease: a nationwide, population-based cohort study","volume":"50","author":"Ng","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.rmed.2023.107329_bib5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.resinv.2021.04.011","article-title":"Guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease","volume":"59","author":"Kondoh","year":"2020","journal-title":"Respir Investig"},{"issue":"9","key":"10.1016\/j.rmed.2023.107329_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11926-013-0359-6","article-title":"Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis","volume":"15","author":"Kiely","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"issue":"6","key":"10.1016\/j.rmed.2023.107329_bib7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00296-004-0472-y","article-title":"Pulmonary involvement in rheumatoid arthritis","volume":"25","author":"Bilgici","year":"2005","journal-title":"Rheumatol. Int."},{"issue":"3","key":"10.1016\/j.rmed.2023.107329_bib8","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/14397595.2019.1621462","article-title":"Related factors, increased mortality and causes of death in patients with rheumatoid arthritis-associated interstitial lung disease","volume":"30","author":"Kakutani","year":"2020","journal-title":"Mod. Rheumatol."},{"issue":"9","key":"10.1016\/j.rmed.2023.107329_bib9","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern. Med. J."},{"issue":"6","key":"10.1016\/j.rmed.2023.107329_bib10","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1164\/rccm.202103-0714OC","article-title":"Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial","volume":"205","author":"Khanna","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10","key":"10.1016\/j.rmed.2023.107329_bib11","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"10038","key":"10.1016\/j.rmed.2023.107329_bib12","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.rmed.2023.107329_bib13","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s40265-019-01178-x","article-title":"Current and emerging drug Therapies for connective tissue disease-interstitial lung disease (CTD-ILD)","volume":"79","author":"Jee","year":"2019","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.rmed.2023.107329_bib14","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an Update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2023.107329_bib15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12890-017-0462-y","article-title":"Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial","volume":"17","author":"Behr","year":"2017","journal-title":"BMC Pulm. Med."},{"issue":"7","key":"10.1016\/j.rmed.2023.107329_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"3","key":"10.1016\/j.rmed.2023.107329_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1378\/chest.13-0844","article-title":"Predicting pulmonary fibrosis disease course from past trends in pulmonary function","volume":"145","author":"Schmidt","year":"2014","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.rmed.2023.107329_bib18","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1164\/rccm.201206-1010PP","article-title":"Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials","volume":"186","author":"du Bois","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"22","key":"10.1016\/j.rmed.2023.107329_bib19","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.rmed.2023.107329_bib20","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"SI","key":"10.1016\/j.rmed.2023.107329_bib21","doi-asserted-by":"crossref","first-page":"SI43","DOI":"10.1093\/rheumatology\/keac325","article-title":"Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease","volume":"62","author":"Kreuter","year":"2022","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.rmed.2023.107329_bib22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.rmed.2023.107329_bib23","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1513\/AnnalsATS.202103-266OC","article-title":"Azithromycin for the treatment of chronic cough in idiopathic pulmonary fibrosis: a randomized controlled crossover trial","volume":"18","author":"Guler","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"5 Suppl 62","key":"10.1016\/j.rmed.2023.107329_bib24","first-page":"S26","article-title":"A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients","volume":"28","author":"Kim","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"issue":"143","key":"10.1016\/j.rmed.2023.107329_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0080-2016","article-title":"Oxygen therapy for interstitial lung disease: a systematic review","volume":"26","author":"Bell","year":"2017","journal-title":"Eur. Respir. Rev."},{"issue":"22","key":"10.1016\/j.rmed.2023.107329_bib26","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1001\/jama.2020.22960","article-title":"Effect of Co-trimoxazole (trimethoprim-sulfamethoxazole) vs placebo on death, lung transplant, or hospital admission in patients with moderate and severe idiopathic pulmonary fibrosis: the EME-TIPAC randomized clinical trial","volume":"324","author":"Wilson","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.rmed.2023.107329_bib27","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients","volume":"59","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.rmed.2023.107329_bib28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.rmed.2009.09.006","article-title":"The SF-36 and SGRQ: validity and first look at minimum important differences in IPF","volume":"104","author":"Swigris","year":"2010","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2023.107329_bib29","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial","volume":"40","author":"Acharya","year":"2020","journal-title":"Rheumatol. Int."},{"issue":"5","key":"10.1016\/j.rmed.2023.107329_bib30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2023.107329_bib31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.resinv.2020.10.005","article-title":"Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: subgroup analysis of the SENSCIS trial","volume":"59","author":"Azuma","year":"2021","journal-title":"Respir Investig"},{"issue":"1","key":"10.1016\/j.rmed.2023.107329_bib32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2023.107329_bib33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14397595.2020.1751402","article-title":"Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: a Japanese population analysis of the SENSCIS trial","volume":"31","author":"Kuwana","year":"2021","journal-title":"Mod. Rheumatol."},{"issue":"3","key":"10.1016\/j.rmed.2023.107329_bib34","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/art.41965","article-title":"Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody atatus and modified rodnan skin thickness score","volume":"74","author":"Kuwana","year":"2022","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"10.1016\/j.rmed.2023.107329_bib35","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1093\/rheumatology\/keac091","article-title":"Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial","volume":"61","author":"Volkmann","year":"2022","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.rmed.2023.107329_bib36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2023.107329_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002859","article-title":"Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression","volume":"9","author":"Khanna","year":"2023","journal-title":"RMD Open"},{"issue":"26","key":"10.1016\/j.rmed.2023.107329_bib38","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2023.107329_bib39","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"150","key":"10.1016\/j.rmed.2023.107329_bib40","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur. Respir. Rev."},{"issue":"2","key":"10.1016\/j.rmed.2023.107329_bib41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.rmed.2023.107329_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10092129","article-title":"Clinical predictors of lung-function decline in systemic-sclerosis-associated interstitial lung disease patients with normal spirometry","volume":"10","author":"Nagy","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.rmed.2023.107329_bib43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/annrheumdis-2020-217230","article-title":"Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)","volume":"80","author":"Spagnolo","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.rmed.2023.107329_bib44","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s12325-020-01578-6","article-title":"Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey","volume":"38","author":"Olson","year":"2021","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.rmed.2023.107329_bib45","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1513\/AnnalsATS.202103-343OC","article-title":"Nintedanib in progressive pulmonary fibrosis: a systematic review and meta-analysis","volume":"19","author":"Ghazipura","year":"2022","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.rmed.2023.107329_bib46","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1513\/AnnalsATS.202103-342OC","article-title":"Pirfenidone in progressive pulmonary fibrosis: a systematic review and meta-analysis","volume":"19","author":"Ghazipura","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.rmed.2023.107329_bib47","article-title":"The efficacy and safety of pirfenidone combined with immunosuppressant therapy in connective tissue disease-associated interstitial lung disease: a 24-week prospective controlled cohort study","volume":"9","author":"Wang","year":"2022","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.rmed.2023.107329_bib48","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12931-021-01668-1","article-title":"Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases","volume":"22","author":"Cottin","year":"2021","journal-title":"Respir. Res."},{"issue":"4","key":"10.1016\/j.rmed.2023.107329_bib49","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jbspin.2006.11.013","article-title":"Biologics in the treatment of primary inflammatory myositis","volume":"74","author":"Wendling","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.rmed.2023.107329_bib50","article-title":"The efficacy and safety of tacrolimus on top of glucocorticoids in the management of IIM-ILD: a retrospective and prospective study","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.rmed.2023.107329_bib51","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.rmed.2023.107329_bib52","series-title":"Combination Therapy of Mycophenolate Mofetil and Pirfenidonevs. Mycophenolate Alone: Results from the Scleroderma Lung Study Lll","author":"Khanna","year":"2022"},{"issue":"6","key":"10.1016\/j.rmed.2023.107329_bib53","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/EDE.0000000000000857","article-title":"Performance of between-study heterogeneity measures in the Cochrane library","volume":"29","author":"Ma","year":"2018","journal-title":"Epidemiology"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611123002172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611123002172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:16:19Z","timestamp":1762337779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611123002172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":53,"alternative-id":["S0954611123002172"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2023.107329","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2023.107329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107329"}}